Several other equities research analysts have also recently issued reports on the stock. Morgan Stanley initiated coverage on shares of Fisher & Paykel Healthcare in a research report on Wednesday, November 16th. They set an overweight rating for the company. Royal Bank of Canada initiated coverage on shares of Fisher & Paykel Healthcare in a report on Wednesday, December 21st. They set an underperform rating for the company. Finally, The Goldman Sachs Group upgraded Fisher & Paykel Healthcare from a neutral rating to a conviction-buy rating in a report on Thursday, November 17th.
Fisher & Paykel Healthcare Stock Performance
Shares of OTCMKTS:FSPKF opened at $16.36 on Monday. Fisher & Paykel Healthcare has a 52-week low of $10.24 and a 52-week high of $20.78. The business has a fifty day moving average of $14.09 and a two-hundred day moving average of $12.89.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital.
- Get a free copy of the StockNews.com research report on Fisher & Paykel Healthcare (FSPKF)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Fisher & Paykel Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fisher & Paykel Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.